Change in relative mobility of M protein following neuraminidase treatment in patients with multiple myeloma and monoclonal gammopathy of undetermined significance.
The aim of this study was to clarify the relationship between the relative mobility of M protein in various disease states using cellulose acetate membrane electrophoresis. To examine the carbohydrate chain of the M protein, sera from patients with multiple myeloma (MM), various cancers, and benign disease were treated with neuraminidase. The relative mobility in benign disease and MM patient sera following neuraminidase treatment varied among individuals, while that of IgG M protein in sera from cancer patients was from 0.2 to 0.3. Thus, the relative mobility in cancer patients was narrower than in those with MM or benign disease.However, after neuraminidase treatment, there was no significant difference between relative mobility in cancer patient's sera and those in other disease patients.
Kurihara
Yuriko
Y
Analytical Laboratory Chemistry, Graduate School of Allied Health Sciences, Tokyo Medical and Dental University, Tokyo, Japan. yuriko.ando.mtec@tmd.ac.jp
Iijima
Shiro
S
Fukushima
Kouhei
K
Hosaka
Toshiaki
T
Shiba
Kiyoko
K
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D004588:Electrophoresis, Cellulose Acetate; D006801:Humans; D007070:Immunoglobulin A / Q000097:blood; D007074:Immunoglobulin G / Q000097:blood; D007075:Immunoglobulin M / Q000097:blood; D007145:Immunoglobulin kappa-Chains; D008875:Middle Aged; D009101:Multiple Myeloma / Q000276:immunology / Q000378:metabolism*; D009194:Myeloma Proteins / Q000378:metabolism*; D009369:Neoplasms / Q000276:immunology / Q000378:metabolism*; D009439:Neuraminidase / Q000494:pharmacology*; D010265:Paraproteinemias / Q000276:immunology / Q000378:metabolism*
D007070:Immunoglobulin A; D007074:Immunoglobulin G; D007075:Immunoglobulin M; D007145:Immunoglobulin kappa-Chains; D009194:Myeloma Proteins; C085016:multiple myeloma M-proteins; D009439:Neuraminidase